Memgen Reports Positive Results for ISF35 in High-Risk Chronic Lymphocytic Leukemia

DALLAS--(BUSINESS WIRE)--Memgen announced today that the ongoing Phase Ib study of its cancer immune therapy, ISF35, has produced positive results, including a complete remission in the trial’s first patient who had 17p deleted chronic lymphocytic leukemia (CLL).

Back to news